A biopharmaceutical company that uses chitin microparticles for the treatment of infectious diseases, Allergies and inflammatory bowel diseases



Products and Markets
The CMP Therapeutics' product pipeline currently comprises:
  • Intranasal OTC Product
    • Target Indications: Common cold, influenza and allergy
    Target Launch date: 2012
    The combination of CMP's principal barrier forming and sanitising action, secondary immunomodulatory properties, excellent safety profile, 'natural origins', and long shelf life means that the product is potentially well suited to the OTC healthcare market. The Company has developed an intranasal OTC product called Atlantic Secret™ for the treatment of the colds, flu and allergies. This product, with its unique mode of action, is registered in the European Market with a target product launch date of 2012 (with the USA to follow).

  • Oral Product
    • Target Indications: allergies and inflammatory bowel disease
    Target Launch date: 2015
    Pre-clinical data has shown that when chitin is administered orally, as CMP, it completely abolishes an allergic response to food. Pre-clinical models suggest there is primarily a mild immuno-regulatory effect operating through chitin-specific receptors (called FIBCD1) that have recently been discovered lining the gastrointestinal tract. Based on these findings from initial work with a multi-national food company, CMP Therapeutics intends to develop oral products containing CMP, such as additives for infant formula. The first clinical studies for allergy will start at the end of 2012 and the first product could be on the Market in early 2015. The Company, in collaboration with the University of Southern Denmark and Kings College London, is also investigating the potential of CMP in the treatment of inflammatory bowel disease.

  • A Mucosal Immunotherapy Adjuvant
    • The immunomodulatory effects of CMP also mean that it can be used as an adjuvant - either alongside mucosal vaccines to boost cell-mediated immunity, or to increase the efficacy of immunotherapy aimed at allergic desensitisation. In vivo studies have shown CMP to be highly effective in both these regards. This aspect will be developed in partnership with vaccine companies.

The Company is developing a number of potential pathways to market for the above products from developing and launching the products themselves to partnering - the ultimate decision on the most appropriate route will be determined with input from Investors.
 

Press Release
CMP Therapeutics gains CE mark for Novel Rhinitis product - Atlantic Secret™.
Download PDF